Stifel Nicolaus Lowers Nyxoah (NASDAQ:NYXH) Price Target to $15.00

Nyxoah (NASDAQ:NYXH) had its price objective decreased by equities researchers at Stifel Nicolaus from $16.00 to $15.00 in a note issued to investors on Friday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ target price would suggest a potential upside of 49.25% from the stock’s previous close.

Separately, HC Wainwright reissued a “buy” rating and set a $17.00 target price on shares of Nyxoah in a research note on Friday, December 13th.

Nyxoah Trading Up 3.3 %

Shares of NYXH opened at $10.05 on Friday. Nyxoah has a 12-month low of $6.76 and a 12-month high of $20.00. The firm has a market capitalization of $342.30 million, a P/E ratio of -5.37 and a beta of 1.42. The firm has a 50-day moving average price of $10.26 and a 200 day moving average price of $9.17. The company has a current ratio of 5.28, a quick ratio of 4.95 and a debt-to-equity ratio of 0.21.

Nyxoah (NASDAQ:NYXH) last posted its quarterly earnings results on Thursday, March 13th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.46) by ($0.03). Nyxoah had a negative net margin of 1,043.93% and a negative return on equity of 51.68%. Sell-side analysts forecast that Nyxoah will post -1.91 EPS for the current year.

Hedge Funds Weigh In On Nyxoah

Several large investors have recently made changes to their positions in NYXH. Kovack Advisors Inc. acquired a new stake in shares of Nyxoah in the third quarter valued at $96,000. LPL Financial LLC acquired a new position in shares of Nyxoah in the fourth quarter valued at approximately $102,000. Walleye Capital LLC grew its holdings in shares of Nyxoah by 23.9% in the fourth quarter. Walleye Capital LLC now owns 14,831 shares of the company’s stock valued at $119,000 after purchasing an additional 2,862 shares in the last quarter. Ameriprise Financial Inc. purchased a new stake in Nyxoah during the 4th quarter worth approximately $135,000. Finally, Geode Capital Management LLC lifted its holdings in Nyxoah by 19.4% during the 4th quarter. Geode Capital Management LLC now owns 17,100 shares of the company’s stock worth $137,000 after buying an additional 2,774 shares in the last quarter.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.